-

Catalent, Inc. to Present at September Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at two upcoming investor conferences.

On September 12, 2023, at 10:50 a.m. ET, the Company will present at the Morgan Stanley 21st Annual Global Healthcare Conference.

On September 13, 2023, at 7:55 a.m. ET, the Company will present at Baird’s 2023 Global Healthcare Conference.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent
Catalent, Inc. (NYSE: CTLT), is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year. For more information, visit www.catalent.com.

Contacts

Investor:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Industry:

Catalent, Inc.

NYSE:CTLT
Release Versions
English

Contacts

Investor:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa...

Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t...

Catalent Completes Successful Debt Refinancing to Support Continued Growth and Innovation

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses....
Back to Newsroom